Table 1:
Models of pediatric cancer in zebrafish
| Cancer | Driver Oncogene | Model | Oncogene Description | Reference |
|---|---|---|---|---|
| T-ALL | Myc | Tg(rag2:EGFP-mMyc) | Amplification of Myc | [15] |
| Myc | Tg(rag2-loxP-dsRED2-loxP-EGFP-mMyc) | Cre inducible Myc amplification | [16] | |
| Myc | Tg(rag2:LDL-EGFP-mMyc); Tg(Hsp70:Cre) | Heat-shock-inducible Myc amplification | [17] | |
| MYC | Tg(rag2:hMYC-ER) | 4-hydroxytamoxifen inducible MYC amplification | [18] | |
| NOTCH | Tg(rag2:NICD-EGFP) | NOTCH1 intracellular domain amplification | [20] | |
| ARID5B | Tg(rag2:ARID5B) | ARID5B amplification | [23] | |
| B-ALL/T-ALL | MYC | Tg(rag2:hMYC) | Mixed-lineage ALL with MYC amplification | [30] |
| B-ALL | TEL(ETV6)-AML1(RUNX1) | Tg(XEF:EGFP-TEL-AML1) or Tg(ZBA:EGFP-TEL-AML1) | TEL-AML1 fusion | [29] |
| AML | AML1-ETO | Tg(hsp70:AML1-ETO) | AML1-ETO fusion | [32] |
| FLT3 | Tg(CMV:FLT3-ITD) or Tg(CMV:FLT3-TKD) | FLT3-ITD (internal tandem duplication) or FLT3-TKD (tyrosine kinase inhibitor resistant mutation D835Y) | [33] | |
| CNS-PNET | nf1a/b | nf1a−/−;nf1b−/− | Loss of nf1a/b | [41] |
| rb1 | rb1−/− | Loss of rb1 | [42,43] | |
| NRAS | Tg(sox10:mCherry-NRASWT) or Tg(sox10:mCherry-NRASQ61R) | Amplification of wild-type or activated NRAS | [39] | |
| NB | MYCN | Tg(dβh:EGFP-MYCN) | Amplification of EGFP-MYCN | [48] |
| MYCN | Tg(dβh:MYCN;dβh:EGFP) | Amplification of MYCN | [49] | |
| cMYC | Tg(dβh:cMYC;dβh:EGFP) | Amplification of cMYC | [53] | |
| ERMS | KRAS | Tg(rag2:KRASG12D) | Activating KRAS mutation | [60] |
| KRAS | Tg(cdh15:KRASG12D) | Activating KRAS mutation | [61] | |
| ARMS | PAX3-FOXO1 | Tg(CMV-GFP-PAX3-FOXO1) | PAX3-FOXO1 fusion | [69] |